Search Results for “ breast cancer ” – Page 13 – media

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Reviewed by Emily Henderson, B.Sc.Apr 17 2023 A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023. The AEGEAN trial evaluated durvalumab given perioperatively, meaning therapy is given both before and after surgery. Participants on the trial received either pre-surgical (neoadjuvant) durvalumab and platinum-based chemotherapy followed by post-surgical (adjuvant) durvalumab or neoadjuvant placebo and chemotherapy followed by adjuvant placebo. These represent the first data presented on the benefits of perioperative immunotherapy for resectable NSCLC and adds to the growing evidence supporting the benefits of both neoadjuvant and adjuvant immunotherapy for these patients. Our goal is to increase cures for lung cancer. ...
- Source: drugdu
- 124
- April 18, 2023
Engineers find cancer cells have remarkable ability to penetrate deep into their environment

In the 1835 Hans Christian Andersen fairy tale “The Princess and the Pea,” a princess is deemed authentic because of her sensitivity to a pea placed under 20 mattresses on her bed. New research from the McKelvey School of Engineering at Washington University in St. Louis has found that like the fabled princess, cancer cells can sense a layer of cells beneath the top collagen layer on which they normally travel, while normal cells cannot. Amit Pathak, an associate professor of mechanical engineering and materials science, and Christopher Walter, a postdoctoral research associate in Pathak’s lab, found that cancer cells have what they term “depth mechanosensing,” or the ability to sense the properties of the distant environments underneath their immediate extracellular matrix. This could mean that the mechanical properties of extracellular matrices located away from the cells could regulate cell migration. Results of their research were published online in Cell Reports on April 5. Pathak ...
- Source: drugdu
- 133
- April 13, 2023
Blood tests may spare cancer patients chemo

A blood test which can detect traces of cancer cells could spare thousands of patients unnecessary chemotherapy every year. A major bowel cancer trial is examining whether the test can show if surgery has removed all of the tumour. Doctors say half of patients with stage 3 bowel cancer are cured by surgery alone so by using chemotherapy they are over-treating many people. About 1,600 bowel cancer patients are being recruited to the UK study. Ben Cooke runs a hair salon on the King’s Road in Chelsea, London, and also works as a stylist for fashion shoots. In early March last year, he noticed some dark blood in his poo. He rang NHS 111 and was sent to A&E. He was diagnosed with stage 3 bowel cancer, which was successfully treated with surgery. The gold standard treatment is to then have intravenous chemotherapy to mop ...
- Source: drugdu
- 122
- April 6, 2023
New Study Shows Promising Results for Targeted Cancer Therapy

A recent study published in the Journal of Clinical Oncology has shown promising results for a new type of cancer therapy. The therapy, known as a targeted therapy, uses drugs that specifically target the genetic mutations that drive the growth of cancer cells. Traditional cancer treatments like chemotherapy and radiation therapy are often associated with serious side effects because they damage healthy cells along with cancer cells. Targeted therapies, on the other hand, are designed to be more precise and have fewer side effects. The new study focused on a targeted therapy called larotrectinib, which is designed to treat cancers that have a specific genetic mutation called NTRK fusion. NTRK fusion is a rare but important genetic alteration that is found in a variety of cancers, including certain types of lung, colon, and breast cancer. The study included 55 patients with NTRK fusion-positive cancer who were treated with larotrectinib. The ...
- Source: drugdu
- 175
- March 20, 2023
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer

Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer. The approval covers the use of Trodelvy (sacituzumab govitecan-hziy) in patients with advanced UC who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor. Trodelvy was approved on the basis of results from Gilead’s Phase II TROPHY study, which evaluated the drug as monotherapy or as a combination therapy in patients with metastatic UC after progression on a platinum-based chemotherapy and PD-1/L1 inhibitor. In 112 patients who were evaluable for efficacy, 27.7% of those who were treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response. The study also found a median duration of response of 7.2 months for those treated ...
- Source: drugdu
- 179
- April 15, 2021
bladder cancer
Researchers identify early changes in BRCA1-positive breast cells

A new study has found that BRCA1-positive breast cells appear to undergo changes before becoming cancerous, which could help identify which patients can benefit from preventative surgery. The study in mice, funded by Cancer Research UK and published today in Nature Communications, found that breast cells with the BRCA1 gene mutation develop changes similar to those seen in late pregnancy before becoming cancerous. The researchers suggest that women with BRCA1 mutations could be screened in the future to monitor changes to their breast cells. This could help to inform decision-making revolving around preventative surgery, by showing who could benefit from this option. After analysing the mammary tissue of mice at various ages carrying the BRCA1 mutation, the researchers analysed breast cells from 12 women who had a BRCA1 mutation and had undergone preventative surgery. The team found that four out of the 12 women had detectable levels of markers of early stages ...
- Source: drugdu
- 215
- March 10, 2021
breast cells
CRUK researchers develop new early-stage rectal cancer treatment

Cancer Research UK (CRUK) researchers have developed a new treatment for early-stage rectal cancer which they say could provide patients with an improved quality of life. In a pilot study of the new treatment option, which combines local keyhole surgery and radiotherapy, researchers found that they could prevent debilitating side effects such as diarrhoea and the need for a permanent colostomy bag. This study, dubbed TREC, enrolled 123 patients with early-stage rectal cancer, with 61 patients receiving the newly-developed treatment approach. In addition, 55 patients were randomised to two treatment approaches – 28 received major surgery and 27 received the new organ preserving treatment. Within the patient population who received the new treatment, 70% were treated successfully, meaning their tumour was removed while preserving the rest of their rectum and the cancer did not return during the three to five-year follow-up period. Patients who received the new treatment also reported ...
- Source: drugdu
- 570
- December 12, 2020
cancer
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer

Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, will be during the first quarter of 2021. There are more than 27,000 new cases of gastric cancer in the US each year, of which approximately one in five are HER2 positive.1,2 For patients with metastatic gastric cancer who progress ...
- Source: drugdu
- 317
- November 4, 2020
gastric cancer
Researchers reveal discovery of new cancer drug fadraciclib

by Institute of Cancer Research Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research, London, in collaboration with the company Cyclacel. It is already being tested in early clinical trials targeting select hematological malignancies and solid tumors. In a new publication in the journal PLOS One, a team of scientists from Cyclacel and the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) describe the discovery of fadraciclib, formerly known as CYC065, and describe its mechanism of action and therapeutic properties. Fadraciclib is a leading dual inhibitor of two cancer-driving proteins from the cyclin-dependent kinase (CDK) family, CDK2 and CDK9. CDK2/9 inhibitor It was designed by improving the chemical ...
- Source: drugdu
- 267
- November 1, 2020
fadraciclib
Mersana’s Lead Cancer ADC Held Up by FDA for Patient’s Death

The FDA held up Mersana’s top antibody-drug conjugate (ADC), XMT-1522 over safety issues following a patient’s death in phase 1 trial, causing a descent in the company’s shares.
- Source: FierceBiotech
- 200
- July 25, 2018
cancer Clinical Trial FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.